International sales grew 5.4% year over year at a constant exchange rate. All regions benefited primarily from continued growth in the Knee category as well as strong commercial execution and new product uptake.Global Knees growth was driven by the strong execution of the company's four-pillar strategy, backed by a solid Persona portfolio and benefits of the ROSA robotics platform. Within Hips, where it lost market share in the last two years, the company expects to accelerate performance in 2024 with the addition of multiple new product offerings, one being the Z1 hip stem in the direct anterior hip category, which recently received an FDA nod.Zimmer Biomet Holdings, Inc. Price Zimmer Biomet Holdings, Inc. price | Zimmer Biomet Holdings, Inc. QuoteFurther, sales growth in the S.E.T. category ( with double-digit growth in the areas of CMFT, upper extremities and sports), together with strong capital sales, improved the overall performance.